Review Article

Association between interleukin-10 (IL-10) polymorphism (-1,082, A/G) and Sjogren’s syndrome: an updated meta-analysis

Sang Wook Kang¹, Su Kang Kim², Kyong Jin Cho³, Chung-Hun Oh⁴,⁵, Ju Yeon Ban¹,⁵

¹Department of Dental Pharmacology, College of Dentistry, Dankook University, Cheonan, Republic of Korea; ²Kohwang Medical Institute, School of Medicine, Kyung Hee University, Seoul, Republic of Korea; ³Department of Ophthalmology, Dankook University Hospital, Republic of Korea; ⁴Department of Oral Physiology, College of Dentistry, Republic of Korea; ⁵Department of Medical Laser, Graduate School, Dankook University, Cheonan, Republic of Korea

Received August 11, 2016; Accepted November 24, 2016; Epub February 15, 2017; Published February 28, 2017

Abstract: To evaluate the association between the polymorphism (-1082, A/G) of the IL-10 gene and a susceptibility for Sjogren’s syndrome (SS). We searched electronic databases including PubMed, Scopus, and Embase databases, and a total of 5 studies including 903 healthy controls and 382 SS cases were analyzed. The meta-analysis of the -1082 polymorphism of the IL-10 gene was carried out with pooled ORs, 95% CI, and p value calculated using the allele, dominant and recessive model. Statistical significance was found in primary SS (pSS) cases in the allele model (G vs. A, OR=0.763, 95% CI=0.610-0.955, P=0.018) and the dominant model (G/G+G/A vs. A/A, OR=0.664, 95% CI=0.479-0.920, P=0.014). Our meta-analysis revealed that the polymorphism (-1,082, A/G) of the IL-10 gene might be related to a susceptibility for pSS.

Keywords: IL-10, polymorphism, case and control study, meta-analysis, Sjogren’s syndrome

Introduction

Interleukin-10 (IL-10) is well known to play a major role in innate and adaptive immune responses [1]. First, it is known to be a cytokine synthesis inhibitory factor due to its role in regulating Th1 activation and cytokine production [2, 3]. IL-10 regulates the growth or differentiation of various immune cells including B cells, NK cells, T cells, etc., and it also controls the human immune response and tolerance [4]. An inhibitory effect on the T lymphocytes of IL-10 mainly occurs through the inhibition of antigen-presenting cells (APC) and MHC class II expression [1]. The dysregulation of IL-10 could affect the immune and inflammatory response, resulting in immuno-deficiency or autoimmunity [5]. A previous study suggested that the polymorphisms in the promoter region of the IL-10 gene could affect IL-10 production and increase the risk of systemic lupus erythematosus [6]. Patients with rheumatoid arthritis also exhibited an association between the promoter polymorphism of the IL-10 gene and autoantibody production [7]. Likewise, several studies have tried to clarify the link between the IL-10 polymorphism and autoimmune disease. Polymorphism (-1, 082) of the IL-10 gene might be useful to predict disease behavior in Crohn’s disease [8], and promoter haplotypes of the gene could be associated with rheumatoid arthritis (RA) [9, 10].

Sjogren’s syndrome (SS) is an autoimmune disease that is characterized by lymphocytic infiltration of exocrine glands, resulting in sicca symptoms of dry eyes and dry mouth [11]. Its annual incidence was reported to vary between 3.9 and 5.3 individuals per 100,000 [12]. SS has also been studied for its inflammatory and autoimmune nature. An increase in the Th1 cytokine expression frequency was reported in minor salivary glands of patients with primary SS [13]. The IL-10 levels in the saliva of SS patients are reported to be correlated with the degree of xerophthalmia and xerostomia [14]. IL-10 protein production has a close association with the IL-10 gene promoter
polymorphism [15]. IL-10 -592, -819, and -1082 are well-known single nucleotide polymorphism in the promoter region of IL-10 gene, and their haplotypes were investigated to show an association with SS [16-20].

These previous studies investigated the association between the IL-10 polymorphism and SS, but the results are not obvious. In 2013, a meta-analysis studied the association between the IL-10 polymorphisms and the development of SS to clarify this association in bigger samples [21]. Since then, two more studies have reported on the relation between the IL-10 polymorphism and the development of SS [16, 22]. Therefore, the aim of this meta-analysis is to update previous meta-analyses and to evaluate the association of the IL-10 polymorphism with a susceptibility for SS.

**Method**

**Search strategy**

To identify all of the eligible studies investigating the association between the IL-10 polymorphism (-1,082, A/G) and a susceptibility for SS, we conducted a systematic literature search in PubMed, Scopus, and Embase databases up to June 1, 2016. The following search terms were used to find these articles: “Sjogren’s Syndrome”, or “SS”, and “IL-10”, “polymorphism”, “polymorphisms”, or “-1,082” and/or “meta analysis”. These keywords were used in combination or in isolation. Previous meta-analyses on the IL-10 (-1,082, A/G) polymorphism and SS were checked as reference, and additional studies were obtained through a manual search of the references of the original studies.

**Inclusion criteria and exclusion criteria**

The studies were included if they met the following criteria: (1) evaluation of the association between the IL-10 polymorphism (-1,082, G/A) and SS; (2) designed using the methodology of a case-control study; (3) contained sufficient distribution of IL-10 polymorphisms (-1,082, A/G) in the SS group and the control group to estimate an odds ratio (OR), 95% confidence interval (CI), and p value. Studies were excluded from the meta-analysis if they consisted of articles with insufficient genetic data or deviated from HWE in the control group.

**Data extraction**

The data were extracted and consensus was reached for all items by the researchers. If the results were different, they would check the data again and have a discussion to come to an agreement. The data extracted from the selected articles included the first author’s name, year of publication, subject population, number of cases and controls, and genotype frequency of the IL-10 polymorphism (-1,082, G/A).

**Statistical analysis**

The meta-analysis was conducted using the comprehensive meta-analysis software (COrporation, NJ, USA). The pooled p value, OR and 95% CI were used to measure the association between the risk for SS and IL-10 polymorphism (-1,082, G/A). The random effects model or the fixed effects model was used and sensitivity analysis was performed to determine the influence of each study on the final results. We first calculated the hetero-
# Meta-analysis of IL-10 -1,082 polymorphism and Sjogren’s syndrome

## Table 1. Information of eligible studies included in the meta-analysis

<table>
<thead>
<tr>
<th>Diseases</th>
<th>Authors (year)</th>
<th>Country</th>
<th>Study design</th>
<th>Ethnicity</th>
<th>Genotyping method</th>
<th>Gender*</th>
<th>Age</th>
<th>Control</th>
<th>Case</th>
<th>Control</th>
<th>Case</th>
<th>HWE</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSS</td>
<td>Vázquez-Villamar et al. 2015</td>
<td>Mexico</td>
<td>Case-control study</td>
<td>Mexican Mestizos</td>
<td>PCR-RFLP</td>
<td>0/111</td>
<td>57±10</td>
<td>72</td>
<td>150</td>
<td>65</td>
<td>157</td>
<td>0.77</td>
</tr>
<tr>
<td>pSS</td>
<td>Font et al. 2002</td>
<td>Spain</td>
<td>Case-control study</td>
<td>Caucasian</td>
<td>Direct sequencing</td>
<td>4/59</td>
<td>57 (20-83)</td>
<td>103</td>
<td>197</td>
<td>61</td>
<td>65</td>
<td>0.229</td>
</tr>
<tr>
<td>pSS</td>
<td>Hulkkonen et al. 2001</td>
<td>Finland</td>
<td>Case-control study</td>
<td>Caucasian</td>
<td>Direct sequencing</td>
<td>2/60</td>
<td>60±11</td>
<td>343</td>
<td>457</td>
<td>65</td>
<td>59</td>
<td>0.479</td>
</tr>
<tr>
<td>sSS</td>
<td>Origuchi et al. 2003**</td>
<td>Japan</td>
<td>Case-control study</td>
<td>Asian</td>
<td>PCR-RFLP</td>
<td>0/19</td>
<td>56.65 (39-77)</td>
<td>37</td>
<td>59</td>
<td>8</td>
<td>30</td>
<td>0.08</td>
</tr>
</tbody>
</table>

* Ratio of gender, male/female; **, no data on genotype method, gender, and age; HWE, Hardy-Weinberg equilibrium.
Meta-analysis of IL-10 -1,082 polymorphism and Sjogren’s syndrome

Table 2. Overall analysis between IL-10 polymorphism (-1,082, A/G) and susceptibility of Sjogren’s syndrome

<table>
<thead>
<tr>
<th>Genotype comparison</th>
<th>Type</th>
<th>Population</th>
<th>Heterogeneity</th>
<th>Model</th>
<th>OR</th>
<th>Association test</th>
<th>Publication bias</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>P</td>
<td>I²</td>
<td></td>
<td>95% CI</td>
<td>bias p</td>
<td></td>
</tr>
<tr>
<td>G vs. A</td>
<td>All</td>
<td>All</td>
<td>0.014</td>
<td>67.953</td>
<td>Random</td>
<td>0.882</td>
<td>0.581-1.340</td>
<td>0.558</td>
</tr>
<tr>
<td></td>
<td>Caucasian</td>
<td>All</td>
<td>0.006</td>
<td>75.899</td>
<td>Random</td>
<td>0.913</td>
<td>0.563-1.480</td>
<td>0.712</td>
</tr>
<tr>
<td>pSS</td>
<td>All</td>
<td>All</td>
<td>0.086</td>
<td>54.579</td>
<td>Fixed</td>
<td>0.763</td>
<td>0.610-0.955</td>
<td>0.018</td>
</tr>
<tr>
<td></td>
<td>Caucasian</td>
<td>All</td>
<td>0.037</td>
<td>69.714</td>
<td>Random</td>
<td>0.762</td>
<td>0.500-1.161</td>
<td>0.206</td>
</tr>
<tr>
<td>GG vs. GA+AA</td>
<td>All</td>
<td>All</td>
<td>0.113</td>
<td>49.842</td>
<td>Fixed</td>
<td>0.86</td>
<td>0.561-1.319</td>
<td>0.49</td>
</tr>
<tr>
<td>pSS</td>
<td>All</td>
<td>All</td>
<td>0.181</td>
<td>41.438</td>
<td>Fixed</td>
<td>0.801</td>
<td>0.517-1.239</td>
<td>0.319</td>
</tr>
<tr>
<td>GG+GA vs. AA</td>
<td>All</td>
<td>All</td>
<td>0.029</td>
<td>62.957</td>
<td>Random</td>
<td>0.755</td>
<td>0.440-1.296</td>
<td>0.309</td>
</tr>
<tr>
<td>pSS</td>
<td>All</td>
<td>Caucasian</td>
<td>0.103</td>
<td>72.128</td>
<td>Random</td>
<td>0.769</td>
<td>0.397-1.486</td>
<td>0.434</td>
</tr>
<tr>
<td></td>
<td>Caucasian</td>
<td>All</td>
<td>0.088</td>
<td>54.158</td>
<td>Fixed</td>
<td>0.664</td>
<td>0.479-0.920</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>Caucasian</td>
<td>All</td>
<td>0.039</td>
<td>69.207</td>
<td>Random</td>
<td>0.613</td>
<td>0.325-1.157</td>
<td>0.131</td>
</tr>
</tbody>
</table>

OR, odds ratio; CI, confidence interval.

geneity of the studies. The heterogeneity assumption was calculated using the chi-square-based Q test and I² test. The random-effects Mantel–Haenszel method was adopted when the result of the Q test was P<0.05 or the I² statistic was >50%. This indicated that a statistically significant heterogeneity was present between the studies. Otherwise, the fixed-effects Mantel-Haenszel method was adopted.

For a meta-analysis of the IL-10 polymorphism (-1,082, G/A), the pooled ORs, 95% CI, and p value were calculated using a combination of the genotype. We evaluated the risks of the “G allele vs. A allele”, “G/G genotype vs. G/A+A/A genotype”, and “G/G+G/A genotype vs. A/A genotype” on the risk of SS, assuming dominant and recessive effects of the variant A allele, respectively [23]. Egger’s linear regression test was performed to observe the publication bias, and P<0.05 was regarded to be a statistically significant evidence of asymmetry.

Result

Study characteristics

Figure 1 shows a flow chart illustrating the search strategy used in this meta-analysis to identify studies that examined the association between the IL-10 polymorphism (-1,082, A/G) and the susceptibility for Sjogren’s syndrome. First, 27 articles were searched through databases including PubMed, Scopus, and Embase. Of the 27 articles, 19 articles were excluded because the papers were obviously irrelevant or were not case and control studies. Three articles that deviated from HWE in the control group were also excluded in meta-analysis. Finally, five articles were included in the meta-analysis, and the characteristics of these eligible articles are summarized in Table 1. There were four articles with primary SS (pSS) and one article with secondary SS (sSS).

IL-10 polymorphism (-1,082, A/G) and susceptibility of Sjogren’s syndrome

We first evaluated the relationship between a susceptibility for SS and the IL-10 polymorphism (-1,082, A/G) (Table 2). No association was observed between the IL-10 polymorphism (-1,082, A/G) and SS in the allele, dominant, and recessive model (P>0.05, respectively). Also, no significant association was observed in the Caucasian population.

Second, we analyzed the relationship between primary SS and the IL-10 polymorphism (-1,082, A/G). In the subgroup analysis according to SS type, the pooled OR, 95% CI, and p value were obtained in the allele model (G vs. A, OR=0.763, 95% CI=0.610-0.955, P=0.018).
and the dominant model (G/G+G/A vs. A/A, OR=0.664, 95% CI=0.479-0.920, P=0.014) (Table 2 and Figure 2). The p value was identified through a sensitivity analysis.

The funnel plots were created by plotting the standard error against the OR for each study. No evidence of asymmetry was indicated in the funnel plots (P>0.05) and Egger’s linear regression test showed that there was no publication bias (P>0.05).

Discussion

Sjogren’s syndrome is one of the more prevalent forms of autoimmune disease with a
complex pathogenesis, and its etiopathogenesis and immunopathology have not yet been completely elucidated. SS is best characterized by the lymphocytic infiltration of the exocrine glands and epithelia, and this causes xerophthalmia and xerostomia [12]. An altered cytokine balance has already been reported in SS patients [24]. IL-10 is a famous cytokine that plays an important role in the inflammatory and immune responses, and its expression patterns could be influenced by genetic factors that cause alterations in the IL-10 expression and disease [1]. Several reports indicated that a reduced expression of IL-10 is associated with the development of some autoimmune disorders [25, 26]. Thus, we have performed this meta-analysis to evaluate the association between the polymorphism (-1082, A/G) of the IL-10 gene and the development of SS.

As mentioned above, a meta-analysis had already examined the association between the IL-10 polymorphism and the development of SS and reported the association of IL-10 and pSS [21]. The study had included a total of 7 articles [17-20, 27-29]. Among these, however, no genotype data had been presented in those written by Limaye et al. and Willeke et al., so these were excluded from the current meta-analysis. The articles by Marka et al. and Gottenberg et al. were also excluded because they were not in Hardy-Weinberg equilibrium, and two recent studies testing for an association between the IL-10 polymorphism and SS were added in this meta-analysis [16, 22]. Finally, a total of 5 studies including 903 healthy controls and 382 SS cases were examined.

Our results showed a statistical significance in pSS, but this result needs to be interpreted carefully. When all SS cases are included (pSS+sSS), there was no significance. However, when we excluded the sSS cases, we found a statistical association. The study by Origuchi et al. was performed in the Japanese population. According to the NCBI HapMap database (http://www.ncbi.nlm.nih.gov), the genotype frequency of polymorphism (-1082, A/G) of the IL-10 gene differs according to ethnicity. The genotype frequency of polymorphism (-1082, A/G) of the IL-10 gene is almost monomorphic in the Japanese population (AA:GA:GG=0.907:0.081:0.011). Since that could have affected our result, the data should be ruled out in the analysis process by using a sensitivity analysis.

Our results showed no association between polymorphism (-1082, A/G) of the IL-10 gene and SS. However, we could not examine the ethnic distribution because most studies included Caucasian populations while only one was carried out with an Asian population. There were too few studies on Asians and no studies on African populations to examine the ethnic distribution of the polymorphism (-1082, A/G) of the IL-10 gene and the development of SS.

Although our result failed to show a statistical association between the IL-10 gene and a susceptibility for SS, our results could show a statistical significance in the allele and genotype distribution in pSS. And no evidence of publication bias or influence of each individual study was observed. Our results showed a possible association between the polymorphism (-1082, A/G) of the IL-10 gene and the development of SS [22, 28].

Acknowledgements

This research was supported by the development of material well-aging center construction project (No. R0004851).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Ju Yeon Ban, Department of Dental Pharmacology, School of Dentistry, Dankook University, Cheonan 31116, Republic of Korea. E-mail: jyban@dankook.ac.kr

References


[23] Park HK and Kim SK. Promoter polymorphisms of NDUFA4 gene were associated with prostate enlargement of benign prostatic hyperplasia. Molecular and Cellular Toxicology 2015; 11: 401-406.

Meta-analysis of IL-10 -1,082 polymorphism and Sjogren’s syndrome


